Liesbeth Fagard

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

Toby M. Maher, Ellen M. van der Aar, Olivier Van de Steen et al. · The Lancet Respiratory Medicine · 2018 · 235 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +7

Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials

Ellen van der Aar, Julie Desrivot, Sonia Dupont et al. · The Journal of Clinical Pharmacology · 2019 · 42 citations · Full text

Pharmacy, Clinical Pharmacokinetics, Pharmacology +10

GLPG1205 for idiopathic pulmonary fibrosis: a phase 2 randomised placebo-controlled trial

Irina Strâmbu, Christian A. Seemayer, Liesbeth Fagard et al. · European Respiratory Journal · 2022 · 39 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Influence of age and renal impairment on the steady state pharmacokinetics of filgotinib, a selective JAK1 inhibitor

Florence Namour, Liesbeth Fagard, Annegret Van der Aa et al. · British Journal of Clinical Pharmacology · 2018 · 31 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis

Amit Taneja, Julie Desrivot, Paul M. Diderichsen et al. · Clinical Pharmacokinetics · 2019 · 13 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +13